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Introduction
Rheumatoid arthritis (RA) is the most common inﬂ  am-
matory arthritis, aﬀ  ecting up to 1% of the adult popu-
lation. RA is characterised by a symmetrical polyarthritis 
in which chronic inﬂ   ammation of joints is associated 
with a progressive destruction of cartilage and bone, 
leading to functional decline and disability. Inﬁ  ltration of 
cells of the innate and adaptive immune system into the 
joint space drives the local production of proinﬂ  am-
matory T-helper type 1 and T-helper type 17 cytokines, 
chemokines, and matrix metalloproteinases by inﬁ  ltrat-
ing monocytes and synovial cells. Proliferation of syno-
vial ﬁ  broblasts leads to the formation of pannus tissue, 
which invades and degrades articular cartilage and 
subchondral bone.
Th   e aetiology of RA is still not understood, but it is well 
accepted that activation of NF-κB-dependent gene 
expres  sion plays a key role in the development of RA and 
many other autoimmune diseases. NF-κB represents a 
family of structurally related and evolutionarily con-
served proteins (p100 or NF-κB2, p105 or NF-κB1, p65 
or RelA, RelB, c-Rel) that function as homodimers or 
heterodimers [1], and that regulate the expression of a 
large number of genes – such as TNF, IL-1, IL-6, cyclo-
oxygenase-2, chemokines, inducible nitric oxide synthase, 
and matrix metalloproteinases – that are involved in RA. 
In addition, TNF and IL-1 are themselves very potent 
activators of NF-κB (reviewed in [2,3]).
NF-κB activation can be detected in cultured synovial 
ﬁ   broblasts and synovial tissue from RA patients, and 
animal models of inﬂ  ammatory arthritis also demonstrate 
the active role of NF-κB in the development and progres-
sion of RA (reviewed in [4]). Th   e time course of NF-κB 
activation appears to precede the onset of disease, and 
blockade of NF-κB by diﬀ  erent means decreases disease 
severity [5,6].
Next to its role in proinﬂ  ammatory gene expression, 
NF-κB is also essential for osteoclastogenesis, mainly by 
mediating the eﬀ   ects of receptor activator of NF-κB 
ligand (RANKL). Defects in the regulation of osteo  clasto-
genesis are the major cause of bone erosion in osteolytic 
diseases such as RA [7].
Finally, recent discoveries revealing a genetic associa-
tion with several genes relevant to NF-κB signalling, 
including CD40, TRAF1, TNFAIP3, and c-REL, further 
highlight the importance of NF-κB activation in RA 
pathogenesis [8].
Pathological triggers of NF-κB signalling in RA
Since NF-κB is central to the process of inﬂ  ammation in 
RA, much research deals with the identiﬁ  cation of the 
molecular triggers that activate NF-κB in RA. It is well 
accepted that proinﬂ  ammatory cytokines such as TNF 
and IL-1 play an important role, and administration of 
TNF antagonists is an eﬀ  ective treatment for severe RA 
(reviewed in [9]). TNF and IL-1 are both very potent 
activators of NF-κB and it can be expected that NF-κB 
activation by these cytokines mediates most of their pro-
inﬂ  ammatory activities in RA (reviewed in [3]).
NF-κB activation by receptor activator of NF-κB 
(RANK), a TNF receptor family member, is important for 
osteoclastogenesis, and defects in proper RANK–NF-κB 
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other diseases associated with bone loss [7]. CD40 is 
another TNF receptor family member that is functionally 
expressed on a variety of cell types, including smooth 
muscle ﬁ  bro  blasts from normal and RA patients and RA 
synovial cells, B cells, macrophages, and dendritic cells, 
and can be upregulated by proinﬂ  ammatory cytokines 
including TNF [10]. Binding of the CD40 ligand (CD154), 
which is transiently expressed on the surface of activated 
CD4+ T  cells, triggers NF-κB activation resulting in 
ﬁ  broblast proliferation and secretion of proinﬂ  ammatory 
cytokines and chemokines, which contributes to joint 
destruction. However, studies with antagonistic anti-
CD40 or anti-CD154 antibodies led to the conclusion 
that CD40 signals may be important at the initial stages 
of arthritis induction, but are not required once disease is 
established and pathogenic antibodies are already present 
[11,12]. Enhanced expression of the TNF receptor family 
member B-cell activating factor (BAFF), allowing the 
survival of autoantibody-producing B lymphocytes, is 
also characteristic for RA, and antagonists of BAFF have 
been developed to counter RA [13]. Finally, lymphotoxin 
β receptor signalling has been implicated in tertiary lym-
phoid organ formation at sites of chronic inﬂ  ammation 
including RA [13].
Toll-like receptors (TLRs) have been implicated in a 
variety of autoimmune diseases and are potential candi-
dates for inducing NF-κB-dependent inﬂ  ammation  in 
RA. In addition to microbial ligands, an increasing 
number of endogenous ligands – a group of proteins 
derived from host tissues and cells – have been reported 
as candidate activators of TLRs inducing so-called sterile 
inﬂ  ammation (reviewed in [14,15]). TLRs are expressed 
in RA synovial tissues and various endogenous ligands 
are present within the inﬂ  amed joints of RA patients. 
Moreover, animal models using TLR knockout mice or 
strategies to block TLR signalling clearly identify TLR-
dependent inﬂ   ammation as being important in the 
pathogenesis of the disease.
High mobility group box chromosomal protein 1 
(HMGB1), a highly conserved chromatin component that 
can be actively secreted by macrophages or passively 
released by necrotic cells, is one of the most putative 
endogenous TLR4 ligands involved in RA pathology. 
HMGB1 is increased in RA synovial tissue and HMGB1 
neutralising antibodies or the antagonistic BoxA domain 
of HMGB1 protect against collagen-induced arthritis in 
mice [16]. Myeloid-related protein 8 and myeloid-related 
protein 14, damage-associated molecular pattern mole-
cules belonging to the S100 family of calcium-binding 
proteins, are also abundantly present in RA synovial 
ﬂ  uid, and have been suggested to be involved in TLR4-
induced chronic inﬂ   ammation in RA [17,18]. Other 
endogenous TLR ligands that may be involved in RA 
pathology are extracellular matrix components such as 
ﬁ  brinogen, ﬁ  bronectin, biglycan, tenascin C, and hyal-
uronic acid fragments (reviewed in [14,15]). Together, 
these studies suggest that several TLR ligands in the 
inﬂ  amed joint tissue may contribute to NF-κB activation 
and inﬂ  ammatory gene expression in RA.
Basic principles of NF-κB signalling
NF-κB proteins are sequestered in the cytoplasm as 
latent complexes by inhibitory proteins referred to as 
inhibitor of NF-κB (IκB) proteins, which prevent NF-κB 
nuclear translocation and DNA binding [19]. Whereas 
the majority of IκBs (IκBα, IκBβ, IκBε, p105 (also known 
as NF-κB1), p100 (also known as NF-κB2)) serve as 
inhibitors of NF-κB, IκBξ and Bcl-3 instead potentiate 
NF-κB transactivation in the nucleus. p100 and p105 are 
precursors of the p52 and p50 NF-κB subunits, respec-
tively. Th   ere are two unique NF-κB signalling pathways, 
termed canonical (or classical) and noncanonical (or 
alter  native) NF-κB pathways.
Th  e canonical NF-κB pathway plays a major role in 
innate and adaptive immunity, and is triggered by many 
stimuli including proinﬂ  ammatory cytokines (for example, 
TNF, IL-1), antigens, RANKL, and TLR ligands. NF-κB 
signalling initiated by diﬀ   erent receptors requires the 
formation of proximal protein–protein interactions that 
are often receptor speciﬁ  c, but ultimately converge in the 
activation of the IκB kinase (IKK) complex, which 
mediates phosphorylation of the inhibitory IκB protein 
leading to its K48-polyubiquitination and degradation by 
the proteasome [20]. Th  e IKK complex is comprised of 
the two catalytic subunits IKK1 and IKK2 (also known as 
IKKα and IKKβ) and the regulatory subunit NF-κB 
essential modulator (NEMO – also known as IKKγ) 
(Figure 1). Gene targeting experiments showed that IKK2 
and NEMO, but not IKK1, are required for canonical NF-
κB activation [21].
One of the best studied NF-κB signalling pathways is 
the TNF pathway. TNF stimulation results in the recruit-
ment of TNF receptor-1-associated death domain 
(TRADD) protein and of receptor interacting protein 1 
(RIP1), which function as adaptor proteins for the E3 
ubiquitin ligases TNF receptor-associated factor (TRAF) 
2 and TRAF5, which in turn bind the E3 ubiquitin ligases 
cellular inhibitor of apoptosis (cIAP) 1 and cIAP2 
(Figure  1). On TNF stimulation, TNF-receptor bound 
RIP1 is rapidly modiﬁ   ed by K63-linked polyubiquitin 
chains. TRAF2/5 and cIAP1/2 are good candidates for 
RIP1 ubiquitination, but the speciﬁ  c role of each is still 
unclear. Th   e poly  ubiquitin chains on RIP1 are believed to 
create a scaﬀ  old to recruit the IKK and TAK1 complex 
via the ubiquitin-binding proteins NEMO and TAB1/2, 
respec tively.  Th   e recent identiﬁ  cation of a distinct E2/E3 
enzyme complex that modiﬁ   es NEMO with linear 
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Page 2 of 11Figure 1. Canonical NF-κB signalling and negative regulators. Ligand engagement of specifi  c membrane receptors such as TNFR1, CD40, 
RANK, and TLR4 trigger the recruitment of specifi  c adaptor proteins (TNF receptor 1-associated death domain protein (TRADD), MyD88, MAL, TIR 
domain-containing adaptor-inducing IFNβ (TRIF)), kinases (RIP1, IRAK1, IRAK4), and ubiquitin ligases (TRAF2, TRAF6, cIAP1, cIAP2) to the receptor. 
K63-linked polyubiquitination of TRAFs, RIP1 and IRAK1, is recognised by NEMO and TAB proteins, resulting in the recruitment and activation of 
respectively IKK2 and TAK1. TAK1 then phosphorylates and activates IKK2, which in turn phosphorylates IκBα, triggering its K48-linked ubiquitination 
and proteasomal degradation. This allows NF-κB (here shown as a heterodimer of p65 and p50) to translocate to the nucleus and promote target 
gene expression. TRAF1, which has no ubiquitin ligase activity, can negatively regulate NF-κB activation, most probably by competing with other 
TRAFs. A20 and CYLD are deubiquitinating enzymes that control NF-κB activation by targeting specifi  c signalling proteins including RIP1 and TRAF6, 
to which they are recruited using specifi  c ubiquitin-binding adaptor proteins such as ABIN-1 and p62. miR-146 is thought to negatively regulate 
TLR signalling by inhibiting expression of IRAK1 and TRAF6. Finally, TLR signalling can also be inhibited by the transmembrane protein SIGIRR, which 
has been proposed to compete with TLR4 for binding to IRAK1 and TRAF6. The expression of many of these negative regulatory molecules is NF-κB 
dependent, implicating them in the negative feedback regulation of NF-κB activation. ABIN, A20-binding inhibitor of NF-κB; cIAP, cellular inhibitor 
of apoptosis; CYLD, cylindromatosis;  IKK, IκB kinase; IκB, inhibitor of NF-κB; IRAK, IL-1R-associated kinase; MyD88, myeloid diff   erentiation primary 
response gene 88; NEMO, NF-κB essential modulator; NF, nuclear factor; RANK, receptor activator of NF-κB; RIP1, receptor interacting protein 1; 
SIGIRR, single-immunoglobulinIL-1 receptor-related; TIR, Toll-like receptor/IL-1R; TRAF, TNF receptor-associated factor; TLR, Toll-like receptor; TNF, 
tumour necrosis factor.
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Page 3 of 11poly  ubiquitin chains and is essential for TNF-activated 
NF-κB signalling adds further complexity [22]. Th  e  exact 
role of protein-anchored polyubiquitin chains remains 
unclear, as it was recently suggested that unanchored 
polyubiquitin chains can directly activate the TAK1 
complex [23].
Similar signalling principles apply to other receptors. For 
example, TLR4 stimulation by lipopolysaccharide induces 
the recruitment of Toll/IL-1 receptor adaptor protein (also 
referred to as Mal) and TRIF-related adap  tor molecule 
(TRAM), which most probably serve as bridg  ing factors to 
recruit myeloid diﬀ  erentiation primary response gene 88 
(MyD88) and TIR domain-contain  ing adaptor-inducing 
IFNβ (TRIF), respectively. MyD88 in turn recruits 
members of the IL-1R-associated kinase (IRAK) family 
and TRAF6, leading to oligomerisa  tion and self-
ubiquitination of TRAF6 [24]. TRIF also recruits TRAF6 
[25] and RIP1 [26] via a direct inter  action. Both pathways 
then activate TAK1 and IKK in a ubiquitination-depen-
dent manner similar to the TNF pathway (Figure 1).
Th  e noncanonical NF-κB pathway can be activated by 
the lymphotoxin β receptor, BAFF receptor, CD40, and 
RANK (Figure 2). In this pathway, p100 is processed by the 
protea  some to p52, which together with the RelB NF-κB 
subunit regulates a distinct set of target genes that control 
B-cell development, secondary lymphoid organ develop-
ment, and osteoclastogenesis [27] Th   e noncanonical NF-κB 
path  way is strictly dependent on IKK1, which is acti  vated 
upon phosphorylation by NF-κB inducing kinase (NIK). 
NIK is predominantly regulated at the post-translational 
level and is present at extremely low levels in most cell 
types. In unstimulated cells, NIK occurs in a cytoplasmic 
complex with TRAF2, TRAF3, and cIAP1/2, which K48-
polyubiquitinates NIK, leading to its continuous degra  da-
tion by the proteasome. Receptor ligation has been shown 
not only to remove TRAF3 from this complex by recruiting 
it to the receptor, but also to attract TRAF2 and cIAP1/2, 
which are essential for subsequent TRAF3 degradation. All 
this contributes to releasing NIK from its constitutive 
degradation, resulting in NIK accumu  lation and IKK1 
phosphorylation [28,29] (Figure 2).
It should be mentioned that CD40, lymphotoxin β 
receptor and RANK mediate the activation of both 
canonical and noncanonical NF-κB signalling pathways. 
Upon binding of their ligand, CD40 and RANK interact 
with several TRAF members, including TRAF1, TRAF2, 
TRAF3, TRAF5, and TRAF6, and this leads to the 
proteolysis of both TRAF2 and TRAF3, which represents 
an important step in the activation of the noncanonical 
pathway as described above. Speciﬁ  c TRAF molecules 
are associated with overlapping and distinct CD40-
mediated functions. For example, in B cells TRAF6 is 
required for CD40-mediated JNK activation and IL-6 
production, while TRAF2 is required for activation of 
NF-κB, and TRAF3 serves as a negative regulator of 
CD40 signalling [30,31].
Negative regulation of NF-κB signalling in RA
Since NF-κB activation is so crucial to many cellular 
processes, a tight regulation of the NF-κB signalling path-
way and the genes it induces is an absolute requirement 
to ﬁ   ne-tune the inﬂ   ammatory response. Moreover, 
terminating an NF-κB response is essential to prevent 
persistent NF-κB activation that may lead to chronic 
inﬂ  ammation and/or tumorigenesis. To achieve this, cells 
employ diﬀ  erent mechanisms, including the expression 
of inhibitory proteins that downregulate NF-κB signalling 
[32]. Below we give an overview of a number of proteins 
that are involved in the dampening or termination of the 
NF-κB response, some of them under the control of 
NF-κB itself and thus acting in a negative feedback loop. 
In addition, we discuss the potential role of these NF-κB 
inhibitory factors in the immuno  pathology of RA. Several 
other proteins involved in the negative regulation of 
NF-κB-dependent inﬂ   ammatory responses, such as 
MyD88s, IRAK-M, and TOLLIP, have been described 
(reviewed in [33]). Th   ese proteins are not discussed here, 
since a link with RA pathology has not yet been reported.
Although IKK1 is a critical component of the non-
canonical NF-κB pathway, it should be mentioned that 
this kinase also plays a prominent role in the negative 
regulation of both canonical and noncanonical NF-κB 
pathways. Macrophages from IKK1-deﬁ   cient mice or 
knockin mice expressing inactive IKK1 show increased 
production of proinﬂ  ammatory cytokines as a result of 
enhanced IKK2 activation and IκBα degradation [34]. 
IKK1 has also been shown to inhibit nuclear NF-κB and 
to downregulate proinﬂ   ammatory signalling by phos-
phory  lating STAT1 [35]. Interestingly, a recent study has 
demonstrated that IKK1 phosphorylates NIK in negative 
feedback regulation of the noncanonical NF-κB pathway 
[36], supporting the idea that IKK1 plays important roles 
in terminating both canonical and noncanonical NF-κB 
pathways with possible implications for chronic inﬂ  am-
matory diseases like RA.
A20 protein
A20 (also known as TNFAIP3) is a ubiquitin-editing 
protein that negatively regulates NF-κB-dependent gene 
expression in response to diﬀ  erent  immune-activating 
stimuli, including TNF, IL-1 and antigens, and the 
trigger  ing of TLRs and the nucleotide-binding oligo-
merisa  tion domain-containing 2 receptor (reviewed in 
[37]). A20 is believed to inhibit NF-κB function by 
deubiquitinating speciﬁ   c NF-κB signalling molecules, 
such as RIP1, RIP2, TRAF6 and MALT1, which disrupts 
speciﬁ  c protein–protein interactions [38-41] (Figure 1). 
Recently, the disruption of interactions between E2 
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E3 ubiquitin ligases (TRAF6, TRAF2 and cIAP1/2) were 
described as another important mechanism used by A20 
to down  regulate NF-κB signalling [42]. Th   e association of 
A20 with its targets requires speciﬁ  c ubiquitin-binding 
adaptor proteins, including A20-binding inhibitor of 
NF-κB (ABIN) 1 and Tax1-binding protein 1 [43-46].
Next to its role in suppressing NF-κB activation, A20 is 
also a strong inhibitor of apoptosis, at least in some cell 
types. Th   e mechanisms by which A20 regulates apoptotic 
signalling, however, are still elusive. A20-deﬁ  cient  mice 
spontaneously develop multiorgan inﬂ  ammation  and 
cachexia and die within 2 weeks of birth, illustrating the 
potent anti-inﬂ  ammatory function of this molecule [46]. 
Figure 2. Noncanonical NF-κB signalling. CD40 and RANK can activate the noncanonical NF-κB pathway that is dependent on NF-κB inducing 
kinase (NIK) expression levels. In unstimulated cells NIK forms a cytosolic complex with the ubiquitin ligases TRAF2, TRAF3 and cIAP1/2, which 
facilitates the K48-linked polyubiquitination and proteasomal degradation of NIK, keeping NIK levels low. Upon ligand binding, TRAF3 is recruited 
to the receptor, where TRAF2 directs nondegradative K63-linked polyubiquitination of cIAP1/2, resulting in their activation. Subsequently cIAP1/2 
directs its K48-linked polyubiquitination to TRAF3, rather than NIK. As a result, TRAF3 is degraded and NIK is stabilised, resulting in increased 
NIK levels in the cell. NIK then phosphorylates and activates IKK1, which mediates NF-κB p100 phosphorylation. This is followed by K48-linked 
polyubiquitination and partial proteasomal degradation of p100 to p52, which forms a heterodimer with RelB to activate transcription. Next to 
TRAF3, TRAF1 has also been identifi  ed as a negative regulator of this pathway, most probably by competing with other TNF receptor-associated 
factors. cIAP, cellular inhibitor of apoptosis; IKK, IκB kinase; NF, nuclear factor; RANK, receptor activator of NF-κB; TRAF, TNF receptor-associated factor; 
TNF, tumour necrosis factor.
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mediated apoptosis, conﬁ  rming its role as an anti  apop  totic 
protein. We recently showed that mice speciﬁ  cally lacking 
A20 in intestinal epithelial cells exhibit increased suscep-
tibility to experimental colitis due to the hyper  sensitivity of 
their intestinal epithelial cells to TNF-induced apoptosis, 
conﬁ  rming A20 as a major anti  apoptotic protein in the 
intestinal epithelium [47]. Two independent studies 
showed that mice lacking A20 in B  cells develop 
autoimmunity due to hyperactive NF-κB responses in B 
cells leading to unrestricted B-cell survival [48,49].
A20 expression has been observed in several cell types 
that play important roles in the pathophysiology of RA, 
such as ﬁ   broblasts, synoviocytes and lymphocytes. 
Interest  ingly, A20 expression is itself regulated by NF-κB 
[50], implicating A20 in the negative feedback regulation 
of NF-κB signalling. Recently, intra-articular injection of 
an A20-expressing adenovirus was shown to reduce the 
severity of synovial inﬂ  ammation and joint destruction in 
a mouse model of collagen-induced arthritis, even in 
untreated joints, in both a prophylactic and therapeutic 
setting. A20 expression in synovial tissue was associated 
with inhibition of NF-κB activity and decreased levels of 
TNF, IL-1β, IL-6, soluble RANKL, monocyte chemo-
attractant protein 1, and IL-17, suggesting that A20 
induces a protective eﬀ  ect in collagen-induced arthritis 
mice through suppression of NF-κB activation and 
NF-κB-dependent gene expression. [51]. Because TNF 
and IL-1β are known to mediate synovitis, pannus 
formation, and erosion of cartilage and bone in RA, the 
decreased serum levels of TNF and IL-1β in A20-
transduced mice might explain the beneﬁ  cial eﬀ  ects in 
the clinical, pathological, and radiological ﬁ  ndings. Th  is 
study also demonstrated that A20 overexpression leads to 
a decrease in the number of activated osteoclasts in joint 
tissue. A20 might therefore minimise joint destruction 
through decreasing the osteoclast number and activity. It 
will be interesting to analyse in future the susceptibility 
of conditional knockout mice that lack A20 in speciﬁ  c 
cell types such as synovial ﬁ  broblasts,  macrophages, 
dendritic cells, B cells or T cells.
Importantly, several SNPs in the human A20 locus have 
been associated with increased susceptibility to develop-
ment of autoimmune pathologies (reviewed in [52]). 
Several genome-wide association studies also revealed a 
clear association between mutations in the A20 locus in 
the 6q23 chromosome and susceptibility to RA [52]. 
Although the identiﬁ  ed variants are not located in a gene, 
they are thought to inﬂ  uence A20 as its nearest gene 
(~150 kb downstream of A20), probably by the presence 
of potential regulatory DNA elements in this region. As 
A20 is required for termination of TNF-induced signals, 
and TNF is the primary inﬂ  ammatory cytokine in RA, 
these ﬁ  ndings reveal A20 as a candidate susceptibility 
locus for RA. How these variants aﬀ   ect normal A20 
activity and how they cause RA, however, remain unclear. 
Recently, Elsby and colleagues functionally evaluated in 
vitro the regulatory ability of RA-associated SNP variants 
on A20 promoter activity, and could show repressed A20 
trans  cription for some of the SNPs investigated [53]. It 
will be of interest to identify the actual causal variants 
and to elucidate the functional consequences of these 
variants. In this context, knockin mice for the corres-
ponding A20 SNPs, combined with mouse models for RA, 
will be very valuable tools.
A20-binding inhibitors of NF-κB
ABIN-1, ABIN-2 and ABIN-3 (also known as TNIP-1, 
TNIP-2, and TNIP-3) were identiﬁ   ed as ubiquitously 
expressed A20 interacting proteins and were shown to 
inhibit NF-κB activation by TNF and several other 
inﬂ   ammatory stimuli upon overexpression. Because 
ABINs contain a speciﬁ  c ubiquitin-binding motif, they 
have been proposed to target A20 to polyubiquitinated 
substrates [43,44]. Similar to A20, ABIN-1 and ABIN-3 
expression is NF-κB dependent, implicating a potential 
role for the A20/ABIN complex in the negative feedback 
regulation of NF-κB activation (reviewed in [54]). Un-
expectedly, both ABIN-1-deﬁ  cient and ABIN-2-deﬁ  cient 
mice exhibit only slightly increased or normal NF-κB 
responses, respectively, possibly reﬂ  ecting  redun  dant 
NF-κB inhibitory activities of multiple ABINs [55,56]. 
Functional ABIN-3 is expressed in humans, but mice 
only express a truncated and inactive form lacking the 
crucial ubiquitin-binding domain [57]. As for A20, 
ABIN-1 also strongly inhibits TNF-induced apoptosis 
[58], and ABIN-1 deﬁ  cient mice die embryonically due to 
TNF-dependent foetal liver apoptosis [56].
Using oligonucleotide microarray analysis, ABIN-1 was 
identiﬁ  ed among TNF-induced genes in human synovio-
cytes, and high levels of ABIN-1 mRNA were detected in 
RA tissue biopsies, indicating a potential role for ABIN-1, 
together with A20, in the negative feedback regulation of 
NF-κB signalling and the pathogenesis of RA [59]. In a 
recent study, inhibition of TLR responses by immuno-
receptor tyrosine-based activation motif (ITAM)-coupled 
recep  tors was shown to depend on the expression of the 
NF-κB inhibitory proteins ABIN-3 and A20. Moreover, 
this protective eﬀ  ect of the ITAM was strongly suppressed 
in inﬂ   ammatory arthritis synovial macrophages [60]. 
Interest  ingly, ABIN-1 poly  morphisms have been asso-
ciated with psoriasis and systemic lupus erythema  tosus 
in humans [61,62]. A high degree of overlap between 
systemic lupus erythematosus and RA susceptibility loci 
might be expected as the two diseases show some clinical 
overlap in joint involvement, autoantibody production, 
systemic features and response to treatments such as B-
cell depletion (rituximab). It will therefore be interesting 
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be associated with systemic lupus erythematosus are also 
associated with RA.
Cylindromatosis protein
Cylindromatosis (CYLD) protein was originally identiﬁ  ed 
as a tumour suppressor involved in familial cylindro-
matosis [63]. CYLD is also involved, however, in diverse 
physiological processes ranging from immunity and 
inﬂ  ammation to cell cycle progression, spermatogenesis, 
and osteoclastogenesis (reviewed in [64]). CYLD is a 
deubiquitinating enzyme that negatively regulates NF-κB 
signalling initiated by TNFR, RANK and T-cell receptor 
stimulation (reviewed in [64]) (Figure 1), by deubiquitina-
ting several NF-κB signalling proteins including NEMO, 
TRAF2, TRAF6, TRAF7, RIP1 and TAK1. Many of these 
are also targeted by A20 and it is still not clear why the 
cell needs A20 as well as CYLD to control NF-κB activa-
tion. As A20 is only expressed in many cell types upon 
stimulation, it has been suggested that this protein 
mainly regulates later phases of NF-κB signalling, where-
as CYLD would regulate constitutive and early signalling. 
In addition, their relative activity might also be cell-type 
dependent [64].
Interestingly, CYLD has been shown to negatively 
regulate RANK signalling and osteoclastogenesis in mice 
[65]. Mice with a genetic deﬁ   ciency of CYLD have 
aberrant osteoclast diﬀ   erentiation and develop severe 
osteoporosis. Osteoclast precursors of these mice are 
hyper-responsive to RANKL-induced diﬀ  erentiation and 
produce more and larger osteoclasts. CYLD expression is 
markedly upregulated under conditions of RANKL-
induced osteoclastogenesis and is recruited to ubiquitin-
ated TRAF6 via the ubiquitin-binding adaptor protein 
p62 (also known as sequestosome 1) [65], followed by the 
CYLD-mediated deubiquitination of TRAF6. In this 
context, it is worth mentioning that transgenic mice 
expressing a mutated form of p62 also display abnormal 
osteoclastogenesis and develop progressive bone loss 
[66]. Th  ese  ﬁ  ndings suggest that CYLD-mediated inhibi-
tion of RANK-induced NF-κB signalling plays a key role 
in the negative regulation of osteoclastogenesis and 
indicate CYLD as a potential genetic factor involved in 
the pathology of bone disorders such as RA.
Single-immunoglobulin IL-1 receptor-related protein
Single-immunoglobulin IL-1 receptor-related (SIGIRR) 
protein, also known as TIR-8, is a member of the TLR/
IL-1R family that has been extensively characterised as an 
inhibitor of IL-1R and TLR signalling, probably through 
direct interaction with these receptors, MyD88, IRAK1 
or TRAF6 [67] (Figure 1). Given the important role of 
IL-1R and TLR signalling in the chronic inﬂ  ammation 
observed in RA [68], a regulatory role for SIGIRR in RA 
is not unlikely. SIGIRR has a very restricted expression 
pattern, being expressed in epithelial cells, monocytes 
and immature dendritic cells, but not in mature macro-
phages [69,70]. Recently, SIGIRR overexpression was 
shown to inhibit the spontaneous release of inﬂ  ammatory 
cytokines by human RA synovial cells. Th  is inhibitory 
function of SIGIRR was further conﬁ  rmed in vivo, since 
SIGIRR-deﬁ  cient mice developed a more severe disease 
in zymosan-induced arthritis, as well as collagen-induced 
arthritis mouse models [70]. It will be interesting to 
compare the expression of SIGIRR in RA patients with its 
expression in control patients, or to investigate whether 
the function of SIGIRR is compromised in RA patients. 
Because of its restricted expression pattern, SIGIRR may 
also be an interesting therapeutic target in RA.
TNF receptor-associated factor 1
TRAF1 is a unique member of the TRAF protein family 
because it lacks a RING ﬁ   nger domain and therefore 
lacks ubiquitin ligase activity. Accumulating data support 
a role for TRAF1 as both a negative and a positive 
modulator of NF-κB signalling by certain TNF family 
receptors, possibly in a cell-type-dependent manner 
[71,72]. Expression of TRAF1 is inducible by TNF and 
overexpression of TRAF1 inhibits TNF-induced NF-κB 
activation. TRAF1-deﬁ  cient T cells are hyper-responsive 
to TNF, with enhanced proliferation and activation of the 
NF-κB signalling pathway. TRAF1 also functions as a 
negative regulator of CD40-induced NF-κB activation. 
TRAF1-deﬁ   cient dendritic cells, however, show 
attenuated responses to secondary stimulation by 
TRAF2-dependent factors, suggesting a positive 
regulatory role in these cells. Th   e mechanism by which 
TRAF1 modulates NF-κB activation is still unclear. 
Most probably, TRAF1 competes with TRAF family 
members for binding to the receptor or other signalling 
proteins. Alternatively, TRAF1 might recruit A20 with 
which it can physically interact [73]. A genome-wide 
association study examining more than 300,000 SNPs 
among approximately 1,500 autoantibody-positive RA 
cases and 1,800 controls identiﬁ  ed a genetic variation at 
the TRAF1–complement component 5 locus as an 
impor  tant RA risk locus [74]. Subsequent work 
indicates that TRAF1 is more likely to be the causative 
locus [75]. Recent work in a Korean population also 
demonstrates genetic association of the TRAF1 region 
with RA [76].
microRNAs
miRNAs are recently discovered regulators of gene expres-
sion and represent a class of noncoding RNA molecules 
essential in many cellular and developmental processes, 
including immune responses and inﬂ  ammation. Th  ey  bind 
the 3’-UTR of target mRNAs leading to the repression of 
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degradation [77].
miR-146a/b and miR-155 are of particular interest for 
inﬂ  ammatory signalling to NF-κB, since these miRNAs 
can be induced by inﬂ  ammatory stimuli such as IL-1β, 
TNF and TLRs [78,79]. In addition, miR-146a is an NF-
κB-dependent gene, and the NF-κB signalling molecules 
IRAK1  and  TRAF6 were identiﬁ   ed as target genes of 
miR-146a [78] (Figure 1). Similarly, miR-155 was shown 
to target transcripts for the NF-κB signalling molecules 
IKKε and RIP1 [79,80]. Notably, both miR-146 and 
miR-155 are expressed at higher levels in RA synovial 
ﬁ   broblasts and synovial tissue [81,82], as well as in 
peripheral blood mononuclear cells of RA patients [83]. 
miR-146a is also overexpressed in CD4+ and IL-17-
producing T cells from RA patients [84,85]. Interestingly, 
a polymorphism in the 3’-UTR of the miR-146a target 
gene was recently shown to be associated with RA 
susceptibility [86]. miR-155 overexpression in synovial 
ﬁ  broblasts was able to prevent the TLR and cytokine-
inducible expression of speciﬁ  c matrix metalloproteinases 
that mediate tissue destruction in RA [81]. Moreover, 
miR-155 was shown to promote TNF production, a key 
process in the pathogenesis of RA [87]. miR-146 and 
miR-155 may therefore be important negative regulators 
of inﬂ   ammation in RA and their potential for the 
development of new treatments is substantial. In 
addition, their increased expression in RA patients is 
potentially useful as a marker for disease diagnosis, 
progression, or treatment eﬃ   cacy [88], but this will require 
conﬁ  rmation using a large and well-deﬁ  ned cohort.
Besides miR-146 and miR-155, a number of other 
miRNAs with a potential role in the control of NF-κB-
dependent inﬂ   ammatory responses in RA pathology 
were recently identiﬁ  ed. In this context, miR-124a – a key 
regulator of the chemokine monocyte chemoattractant 
protein 1 – was shown to be decreased in synoviocytes 
from RA patients [89]. Similarly, elevated levels of 
miR-203 – leading to increased secretion of matrix 
metallo  proteinase-1 and IL-6 – were detected in RA 
synovial ﬁ  broblasts [90]. Finally, miR-16, miR-132, and 
miR-223 were also shown to have an altered expression 
in RA patients, indicating their potential as diagnostic 
biomarkers for pathogenesis [83,88,91].
Conclusions
Th  e NF-κB family of transcription factors plays crucial 
roles in the inﬂ   ammatory processes in RA leading to 
cartilage and bone destruction. Keeping NF-κB activation 
under control can thus be very important for the design of 
speciﬁ  c therapeutics. Th  e existence of multiple negative 
regulators ensuring a tight regulation of the NF-κB 
pathway, however, raises the question of the speciﬁ  c role 
of each of these regulators and the relationship between 
them. In addition, given the number of miRNAs in 
humans and the multiple mRNAs they target, intense 
complexity can be expected. How all these regulatory 
signals are themselves regulated will be an important 
question in order to clarify how NF-κB signalling is 
organised, and, more importantly, how this knowledge 
may lead to new treatments for inﬂ  ammatory diseases 
such as RA.
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